This page contains a Flash digital edition of a book.
Activities of Daily Living Subscale for Early Parkinson’s Disease neurotoxin, N-methyl(R)salsolinol, J Neurochem, 2001;78:727–35.


48. Blandini F, Armentero MT, Fancellu R, et al., Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease, Exp Neurol, 2004;187:455–9.


49. Finberg JP, Wang J, Bankiewicz K, et al., Increased striatal dopamine production from L-DOPA following selective inhibition of monoamine oxidase B by R(+)-N-propargyl-1-aminoindan (rasagiline) in the monkey, J Neural Transm Suppl, 1998;52:279–85.


50. Leegwater-Kim J, Bortan E, The role of rasagiline in the treatment of Parkinson's disease, Clin Interv Aging, 2010;5:149–56.


51. Bar-Am O, Amit T, Youdim MB, Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitro, J Neurochem, 2007;103:500–8.


52. Olanow CW, Rascol O, Hauser R, et al., ADAGIO Study Investigators, A double-blind, delayed-start trial of rasagiline in Parkinson's disease, N Engl J Med, 2009;361:1268–78.


53. Deftereos SN, Andronis CA, Discordant effects of rasagiline doses in Parkinson disease, Nat Rev Neurol, 2010;6:1p following 410.


54. Sampaio C, Ferreira JJ, Parkinson disease: ADAGIO trial hints that rasagiline slows disease progression, Nat Rev Neurol, 2010;6:126–8.


55. Mehta SH, Morgan JC, Sethi KD, Does rasagiline have a disease-modifying effect on Parkinson's disease?, Curr Neurol Neurosci Rep, 2010;10:413–6.


56. Sampaio C, Can focusing on UPDRS Part II make assessments


of Parkinson disease progression more efficient?, Nat Clin Pract Neurol, 2009;5:130–1.


57. NINDS NET-PD Investigators, A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease, Neurology, 2007;68:20–8.


58. Khan M, Gross J, Haupt H, et al., A pilot clinical trial of the effects of coenzyme Q10 on chronic tinnitus aurium, Otolaryngol Head Neck Surg, 2007;136:72–7.


59. Friedman JH, Alves G, Hagell P, et al., Fatigue rating scales critique and recommendations by the Movement Disorders Society task force on rating scales for Parkinson's disease, Mov Disord, 2010;25:805–22.


60. Brown RG, Dittner A, Findley L, Wessely SC, The Parkinson fatigue scale, Parkinsonism Relat Disord, 2005;11:49–55.


61. Parkinson Study Group, A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease, Arch Neurol, 2004;61:561–6.


62. Hauser RA, Lew MF, Hurtig HI, et al., TEMPO Open-label Study Group, Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease, Mov Disord, 2009;24:564–73.


63. Waters CH, Kurth M, Bailey P, et al., Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. The Tolcapone Stable Study Group, Neurology, 1997;49:665–71.


64. Welsh MD, Dorflinger E, Chernik D, Waters C, Illness impact and adjustment to Parkinson's disease: before and after treatment with tolcapone, Mov Disord, 2000;15:497–502.


65. Olanow CW, Kieburtz K, Stern M, et al., US01 Study Team,


Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease, Arch Neurol, 2004;61:1563–8.


66. Goetz CG, Tilley BC, Shaftman SR, et al., Movement Disorder Society UPDRS Revision Task Force, Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results, Mov Disord, 2008;23:2129–70.


67. Schapira AH, Albrecht S, Barone P, et al., Rationale for delayed-start study of pramipexole in Parkinson's disease: the PROUD study, Mov Disord, 2010;25:162–32.


68. Clarke CE, Are delayed-start design trials to show neuroprotection in Parkinson's disease fundamentally flawed?, Mov Disord, 2008;23:784–9.


69. D'Agostino RB Sr, The delayed-start study design, N Engl J Med, 2009;361:1304–6.


70. Merello M, Gerschcovich ER, Ballesteros D, Cerquetti D, Correlation between the Movement Disorders Society Unified Parkinson's Disease rating scale (MDS-UPDRS) and the Unified Parkinson's Disease rating scale (UPDRS) during l-dopa acute challenge, Parkinsonism Relat Disord, 2011;17:705–7.


71. Gallagher DA, Goetz CG, Stebbins G, et al., Validation of the MDS-UPDRS Part I for nonmotor symptoms in Parkinson's disease, Mov Disord, 2011; (Epub ahead of print).


72. Movement Disorder Virtual University, Unified Parkinson's Disease Rating Scale, 2008. Available at: www.mdvu.org/ library/ratingscales/pd/updrs.pdf (accessed January 9, 2012).


US NEUROLOGY


99


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96  |  Page 97  |  Page 98  |  Page 99  |  Page 100  |  Page 101  |  Page 102  |  Page 103  |  Page 104  |  Page 105  |  Page 106  |  Page 107  |  Page 108